Description du projet
Plateforme innovante de détection des biomarqueurs du cancer du sein à un stade précoce dans les exosomes extraits du sang
Dans le cas du cancer du sein, la détection précoce augmente énormément le taux de survie. Les exosomes sont des particules libérées par les cellules dans les fluides corporels. Ils sont devenus des biomarqueurs pour la biopsie liquide, car ils sont porteurs d’informations sur la cellule d’origine. Financé par le programme Actions Marie Skłodowska-Curie, le projet EXCEED vise à développer une plateforme destinée à l’isolement et à la caractérisation optique sans marquage des exosomes extraits du sang. La plateforme combinera l’imagerie sans marquage de la microscopie interférométrique et les informations sur le contenu chimique obtenues par la spectroscopie Raman. Elle sera testée en utilisant les exosomes issus des cellules tumorales afin de déterminer les biomarqueurs possibles à des fins de diagnostic. La validation finale de la plateforme sera réalisée sur des donneurs sains et des patientes atteintes du cancer du sein.
Objectif
Breast cancer is the most common cancer among women worldwide. Early detection is the most critical element, as the survival rate increases by up to 99%. Although there are conventional screening techniques such as mammography, breast cancer is still the second leading cause of cancer death in women. One of the holy grails in cancer research is to develop a blood test for early detection. Sensitive, non-invasive, and easy-to-use liquid biopsy techniques will revolutionize cancer diagnosis and treatment monitoring. The goal of this project is to develop a complete platform for the isolation and label-free optical characterization of biological nanoparticles called exosomes extracted from blood. Exosomes are secreted from the cells into the body fluids and play an important role in intercellular communication. These particles are emerged as potential biomarkers for liquid biopsy applications, as they carry information about their original cell. However, the translation of exosome-based analyses from research labs to clinical settings is limited due to the lack of efficient isolation and quantification tools available. We aim to develop a novel exosome characterization platform, named multimodal Interferometric-Raman imaging platform to detect and quantify exosomes at a single-particle level without using any labels. The combination of the label-free imaging capability of interferometric microscopy and the chemical content information provided by Raman spectroscopy will be an important step for exosome-based diagnostics applications. The proposed system will be integrated into a state-of-the-art isolation tool, creating complete isolation and multiparameter characterization platform. The proposed platform will be tested with the exosomes isolated from tumor cells to determine possible biomarkers that can be used for diagnosis. The diagnostic capability of the system will be validated with healthy donors and breast cancer patients(30 persons each)
Champ scientifique
- natural sciencesbiological sciencescell biology
- natural sciencesphysical sciencesopticsmicroscopy
- medical and health sciencesclinical medicineoncologybreast cancer
- engineering and technologymedical engineeringmedical laboratory technologylaboratory samples analysis
- natural sciencesphysical sciencesopticsspectroscopy
Mots‑clés
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Régime de financement
MSCA-PF - MSCA-PFCoordinateur
34450 Istanbul
Turquie